Sign in
Taking people in United StatesNo phase

Studying T Cell Responses During Anti-PD-1 Therapy in Melanoma and Lung Cancer

Monitors T cells during anti-PD-1 treatment in people with melanoma or lung cancer.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Status
Recruiting
People taking part
500 people, planned
Started
15 Jun 2015
Expected to end
31 Dec 2028
Type of study
Observational
Treatments tested
  • Biospecimen Collection
  • Electronic Health Record Review
Record updated
18 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with locally advanced or stage IV cancer, such as melanoma or lung cancer, who are about to start anti-PD-1 or anti-PD-L1 treatment. Blood samples are taken to follow T cell responses.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Locally or regionally advanced cancer, or stage IV cancer, confirmed by tissue examination.
Earlier treatment
The treating doctor must consider anti-PD-1/anti-PD-L1 therapy appropriate to start. Earlier immune checkpoint inhibitor treatment is allowed.

Main reasons for not taking part

  • Cannot understand the consent form or follow the trial rules
  • Receiving any other anti-cancer treatment or investigational drug at the same time (anti-PD-1/anti-PD-L1 is allowed)
  • Pregnant or nursing
  • Could become pregnant and unwilling to use adequate contraception

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Are 18 years of age or older
  • Have histologic evidence of locally or regionally advanced or stage IV malignancy
  • Are considered appropriate for starting therapy with anti-PD-1/anti-PD-L1 monoclonal antibody by their treating physician (prior therapy with immune checkpoint inhibitor (ICI) is allowed)
  • Have an understanding of the protocol and its requirements, risks, and discomforts
  • Are willing to undergo peripheral blood collection at the time points mentioned in the protocol
  • Are able and willing to sign an informed consent

Who cannot take part

  • Patients receiving any concurrent anti-cancer therapy or investigational agents (with the exception of an anti-PD-1/anti-PD-L1 agent as mentioned above)
  • Inability on the part of the patient to understand the informed consent or be compliant with the protocol
  • Patients who are pregnant, nursing, or are of childbearing potential and are unwilling to employ adequate contraception

Where in United States

  • Mayo Clinic in RochesterRochester, United StatesContact: Clinical Trials Referral OfficeTaking people

About the trial

What the trial wants to find out

This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other cancer types. Measuring levels of specific targets such as Bim and soluble PD-L1 during therapy may help track treatment resistance and clinical outcomes. This information may also help researchers determine why some people with melanoma, lung and other cancer types respond to PD-1/PD-L1 treatment and others do not.

The group in the trial

  • Observational (Blood and stool sample collection)

    Patients undergo blood sample collection throughout the study. Patients also undergo optional stool sample collection and have their medical records reviewed on study. In addition, patients provide previously-collected tissue sample, if available.

    Treatment: Biospecimen Collection and Electronic Health Record Review

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Maximizing Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Plain-language title
Studying T Cell Responses During Anti-PD-1 Therapy in Melanoma and Lung CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
18 June 2026